• Mashup Score: 8
    Advances in BPDCN - 2 year(s) ago

    Naveen Pemmaraju, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, gives an update on the the…

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      @VJHemOnc caught up with @doctorpemm (@MDAndersonNews) on the latest advances in the field of #BPDCN 📰Discussing tagraxofusp, IMGN632, venetoclax, & CNS involvement: https://t.co/OgVPmfWfk5 #IACH2021 @TheIACH #HemOnc #ImmunOnc #CaxTx

  • Mashup Score: 0
    The role of the Pin1/PML/P53 axis in AML - 2 year(s) ago

    Ali Bazarbachi, MD, of the American University of Beirut, Beirut, Lebanon, outlines the role of the Pin1/PML/P53 axis in acute…

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      Ali Bazarbachi (@AUB_Lebanon) spoke with @VJHemOnc on the role of the Pin1/PML/P53 axis in #AML Learn more: 👉https://t.co/RaDKr3EFxO #IACH2021 @TheIACH #LEUsm #HemOnc #Leukemia #AMLsm

  • Mashup Score: 2
    Recent advances in the management of acute GvHD - 3 year(s) ago

    Iskra Pusic, MD, Washington University in St. Louis, St. Louis, MO, discusses recent advances in the management of acute graft-versus-host…

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      Iskra Pusic of @WUSTL discusses recent advances in the management of acute #GvHD & their implications for clinical practice: https://t.co/UI2ukoFYiM #IACH2021 @TheIACH #MMsm #LEUsm #LYMsm #HemOnc #BMTsm

  • Mashup Score: 0
    Post-transplant cyclophosphamide in chronic GvHD - 3 year(s) ago

    Arnon Nagler, MD, MSc, Chaim Sheba Medical Center, Tel-Hashomer, Israel, gives an overview of the latest advances in the treatment…

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      @VJHemOnc caught up w/ Arnon Nagler on the latest advances in the treatment of chronic #GvHD Hear the latest on post-transplant cyclophosphamide & more: https://t.co/L8poo5ljb0 #IACH2021 @TheIACH #MMsm #LEUsm #LYMsm #HemOnc #BMTsm

  • Mashup Score: 3
    VJHemOnc – The video journal of hematological oncology - 3 year(s) ago

    The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve the awareness and understanding of hematological cancers

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      After a thoroughly engaging first day, be prepared for day 2 of the @RHsct2 workshop! Want to hear the latest developments in #BMTsm, #Transplantation, #CellTherapy and more? Join us at 👉https://t.co/O9p0vDBrzw👈 for the key coverage 💻 @VJHemOnc @RHsct2 #HCT #HemOnc https://t.co/NIGPcjQNM4

    • Profile photo of VJHemOnc
      VJHemOnc

      If you missed #IACH2021 or want to listen to some of the sessions again, we’ve got you covered! Head to https://t.co/O9p0vDBrzw for all the interviews and updates from the fourth annual IACH meeting 💻🎥 @VJHemOnc @TheIACH #MMsm #LEUsm #LYMsm #HemOnc https://t.co/6sqMbsIxYr

  • Mashup Score: 2
    IACH 2021: CAR-T in clinical practice - 3 year(s) ago

    Currently, five chimeric antigen receptor T-cell (CAR-T) therapies are approved for the treatment of hematological malignancies including acute lymphoblastic leukemia,…

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      #VJSounds | IACH 2021: CAR-T therapy in clinical practice 👩‍⚕️👨‍⚕️ Hear from Arnon Nagler, Anna Sureda, Christian Chabannon and Arnon Kater as they discuss updates in CAR-T therapy from #IACH2021! 🎧 Listen: https://t.co/m5OsOVoDab @VJHemOnc #CART #HemOnc #ImmunoOnc #LYMsm #LEUsm

  • Mashup Score: 6
    VJHemOnc – The video journal of hematological oncology - 3 year(s) ago

    The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve the awareness and understanding of hematological cancers

    Source: VJHemOnc
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of CyclingDoctor
      CyclingDoctor

      RT @VJHemOnc: 🚨 Did you miss out on #IACH2021? 🚨 📣 Catch up by heading to https://t.co/O9p0vDBrzw for on-demand sessions with leading expe…

    • Profile photo of VJHemOnc
      VJHemOnc

      🚨 Did you miss out on #IACH2021? 🚨 📣 Catch up by heading to https://t.co/O9p0vDBrzw for on-demand sessions with leading experts in #HemOnc, who discussed ground-breaking updates in the field! 👨‍⚕️👩‍⚕️ @VJHemOnc @TheIACH @Mohty_EBMT #MMsm #LEUsm #LYMsm https://t.co/2TvxZByjBT

  • Mashup Score: 3
    VJHemOnc – The video journal of hematological oncology - 3 year(s) ago

    The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve the awareness and understanding of hematological cancers

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      #IACH2021 is now over, and we’d like to say a huge thanks to all the incredible speakers! We hope you found it as informative and enjoyable it as we did. To catch up on the event, head to https://t.co/O9p0vDBrzw! 👨‍⚕️👩‍⚕️💻 @VJHemOnc @TheIACH #MMsm #LEUsm #LYMsm #HemOnc https://t.co/mJQn4zLAw3

    • Profile photo of VJHemOnc
      VJHemOnc

      A massive thank you to the #HemOnc experts who presented at this year’s #MDS21 and a special thanks to the experts who spoke with us 👩‍⚕️👨‍⚕️ Couldn’t make it? Catch up here 👉https://t.co/O9p0vDjQaW👈 @VJHemOnc @MDSFoundation #MDSsm #AMLsm

  • Mashup Score: 0
    Cord blood vs mismatched unrelated donor alloHCT in AML - 3 year(s) ago

    Bhagirathbhai Dholaria, MBBS, of Vanderbilt University Medical Center, Nashville, TN, gives an update on the use of cord blood transplantation…

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      Bhagirathbhai Dholaria of @VUMC_MD talks on the use of cord blood vs mismatched unrelated donor alloHCT in AML 👨‍⚕️💭 Watch her 👉https://t.co/UpxxTyPx9F👈 @VJHemOnc @TheIACH #IACH2021 #LEUsm #AMLsm #HemOnc #BMTsm

  • Mashup Score: 5
    Ide-cel: EC approval and updated results from KarMMa - 3 year(s) ago

    In March 2021, idecabtagene vicleucel (ide-cel) became the first B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T-cell therapy to be approved for the treatment of adults with relapsed/refractory (R/R) multiple myeloma (MM).

    Source: multiplemyelomahub.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of MM_Hub
      MM_Hub

      CONGRESS | #IACH2021 | Reviewing the data of #CARTs in #myeloma, @Mohty_EBMT points out the OS numbers reported in the KarMMA trial, which could mean these pts can be salvaged after CAR-T cell therapy. @TheIACH #mmsm https://t.co/5CAbD2IuMz

Load More